OBJECTIVES: The aim of this study is to evaluate the cost-utility of the treatment, starting with EFZ-based therapy, compared with NVP-based therapy in Thai HIV/AIDS patients. MATERIAL AND METHOD: The study adopted a health care provider perspective. A probabilistic Markov model was applied to Thai HIV/AIDS patients aged 15 to 65 years. Input parameters were extracted from a cohort study of four regional hospitals. The study explored the effects of uncertainty around input parameters. RESULTS: For those patients with a different baseline CD4, initial therapy using EFZ-based regimens was the preferable choice for all subgroups. Given a maximum acceptable willingness to pay (WTP) threshold of 300,000 Baht/DALY averted starting with EFZ-based regimens was cost-effective for patients with a baseline CD4 count less than 250 cells/mm3 and in all patient age groups, except those who were 20 years old. CONCLUSIONS: The results suggest that starting with EFZ-based regimens was the preferable choice and it should be used as the first line regimen for Thai HIV/AIDS patients.
OBJECTIVES: The aim of this study is to evaluate the cost-utility of the treatment, starting with EFZ-based therapy, compared with NVP-based therapy in Thai HIV/AIDSpatients. MATERIAL AND METHOD: The study adopted a health care provider perspective. A probabilistic Markov model was applied to Thai HIV/AIDSpatients aged 15 to 65 years. Input parameters were extracted from a cohort study of four regional hospitals. The study explored the effects of uncertainty around input parameters. RESULTS: For those patients with a different baseline CD4, initial therapy using EFZ-based regimens was the preferable choice for all subgroups. Given a maximum acceptable willingness to pay (WTP) threshold of 300,000 Baht/DALY averted starting with EFZ-based regimens was cost-effective for patients with a baseline CD4 count less than 250 cells/mm3 and in all patient age groups, except those who were 20 years old. CONCLUSIONS: The results suggest that starting with EFZ-based regimens was the preferable choice and it should be used as the first line regimen for Thai HIV/AIDSpatients.
Authors: Andrea L Wirtz; Brian Wilson Weir; Sandra Hsu Hnin Mon; Pachara Sirivongrangson; Tareerat Chemnasiri; Eileen F Dunne; Anchalee Varangrat; Andrew C Hickey; Michele R Decker; Stefan Baral; Kamolnetr Okanurak; Patrick Sullivan; Rachel Valencia; Michael C Thigpen; Timothy H Holtz; Philip A Mock; Betsy Cadwell; Adeola Adeyeye; James F Rooney; Chris Beyrer Journal: JMIR Res Protoc Date: 2020-01-27
Authors: Andrew P Craig; Hla-Hla Thein; Lei Zhang; Richard T Gray; Klara Henderson; David Wilson; Marelize Gorgens; David P Wilson Journal: J Int AIDS Soc Date: 2014-02-25 Impact factor: 5.396